Chinook Therapeutics to Present at Upcoming Investor Conferences
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced participation in upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced participation in upcoming investor conferences. The company will present at the Credit Suisse 31st Annual Healthcare Conference on November 9 at 1:25 PM EST and hold a fireside chat at the Stifel Healthcare Conference 2022 on November 15 at 3:35 PM EST. Interested investors can access the audio webcasts and recordings on the company’s website for up to 90 days after the events. Chinook focuses on precision medicines for kidney diseases, highlighting its leading programs including atrasentan and BION-1301.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was +0.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor conferences:
- Credit Suisse 31st Annual Healthcare Conference – Presentation on Wednesday, November 9th at 1:25 pm EST.
- Stifel Healthcare Conference 2022 – Fireside chat on Tuesday, November 15th at 3:35 pm EST.
To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. The archived audio webcasts will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.